Clinical trial · Observational
Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
Based on Plasma Exosomes Combined With Multi-omics Analysis to Reveal the Trajectory of Targeted Therapy Resistance and Novel Target Intervention Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this observational study is to explore the therapeutic trajectory of targeted therapy in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations. The main objective is to identify potential biomarkers that can predict the efficacy of targeted therapy through plasma exosomes and to explore strategies to reverse drug resistance to targeted therapy. Biological specimens and medical imaging data will be collected from patients already receiving targeted therapy as a first-line treatment, and followed-up will be conducted to analyze prognosis based on different patterns.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| EGFR Activating Mutation | — | UNRESOLVED | — |
| Lung Adenocarcinoma | Lung Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Untreated EGFR mutated lung adenocarcinoma patients
- description
- Patients diagnosed with lung adenocarcinoma with EGFR mutations for the first time.
- interventionNames
- Other: observational study
- label
- Patients with EGFR-mutated lung adenocarcinoma who are responding to targeted therapy
- description
- Patients with EGFR-mutated lung adenocarcinoma treated with targeted therapy combined with or without chemotherapy as first-line therapy, and the therapeutic effect was in the response stage.
- interventionNames
- Other: observational study
- label
- Patients with EGFR-mutated lung adenocarcinoma who are resistant to targeted therapy
- description
- Patients with EGFR-mutated lung adenocarcinoma treated with targeted therapy combined with or without chemotherapy as first-line therapy, and the therapeutic effect was in drug resistance stage, or disease progression.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological examination confirmed lung adenocarcinoma * No other type of tumor was present * Common sensitive EGFR (Ex19Del L858R or combined with other sites) mutations have been identified * Receive targeted therapy with or without chemotherapy as first-line treatment * ≥ 18 years and ≤80 years old Exclusion Criteria: * History of other malignant tumors * Irregular treatment or poor compliance * Incomplete clinical information or lost to follow-up
References
Publications (0)
Data not yet available